<SEC-DOCUMENT>0001144204-13-055151.txt : 20131015
<SEC-HEADER>0001144204-13-055151.hdr.sgml : 20131014
<ACCEPTANCE-DATETIME>20131015121720
ACCESSION NUMBER:		0001144204-13-055151
CONFORMED SUBMISSION TYPE:	8-K
PUBLIC DOCUMENT COUNT:		4
CONFORMED PERIOD OF REPORT:	20131009
ITEM INFORMATION:		Entry into a Material Definitive Agreement
ITEM INFORMATION:		Other Events
ITEM INFORMATION:		Financial Statements and Exhibits
FILED AS OF DATE:		20131015
DATE AS OF CHANGE:		20131015

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			TRANSGENOMIC INC
		CENTRAL INDEX KEY:			0001043961
		STANDARD INDUSTRIAL CLASSIFICATION:	LABORATORY ANALYTICAL INSTRUMENTS [3826]
		IRS NUMBER:				911789357
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		8-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	000-30975
		FILM NUMBER:		131151052

	BUSINESS ADDRESS:	
		STREET 1:		12325 EMMET ST
		CITY:			OMAHA
		STATE:			NE
		ZIP:			68164
		BUSINESS PHONE:		4027385480

	MAIL ADDRESS:	
		STREET 1:		12325 EMMET STREET
		CITY:			OMAHA
		STATE:			NE
		ZIP:			68164
</SEC-HEADER>
<DOCUMENT>
<TYPE>8-K
<SEQUENCE>1
<FILENAME>v357358_8k.htm
<DESCRIPTION>FORM 8-K
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="margin: 0">&nbsp;&nbsp;</P>

<P STYLE="font: bold 18pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">UNITED STATES<BR>
SECURITIES AND EXCHANGE COMMISSION</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">Washington, D.C. 20549</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: bold 18pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">FORM 8-K</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">CURRENT REPORT</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">Pursuant to Section 13 or 15(d) of<BR>
the Securities Exchange Act of 1934</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">Date of Report (Date of earliest event
reported): October 9, 2013</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: bold 18pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">TRANSGENOMIC, INC.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-weight: normal">(Exact
name of registrant as specified in its charter)</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 41%; padding-right: 5.75pt; padding-left: 5.75pt; text-align: center"><B>Delaware</B><BR>
(State or other jurisdiction of incorporation)</TD>
    <TD STYLE="width: 26%; padding-right: 5.75pt; padding-left: 5.75pt; text-align: center">&nbsp;</TD>
    <TD STYLE="width: 33%; padding-right: 5.75pt; padding-left: 5.75pt; text-align: center"><B>000-30975</B><BR>
(Commission File Number)</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding-right: 5.75pt; padding-left: 5.75pt; text-align: center">&nbsp;</TD>
    <TD STYLE="padding-right: 5.75pt; padding-left: 5.75pt; text-align: center">&nbsp;</TD>
    <TD STYLE="padding-right: 5.75pt; padding-left: 5.75pt; text-align: center">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD COLSPAN="3" STYLE="padding-right: 5.75pt; padding-left: 5.75pt; text-align: center"><B>91-1789357</B><BR>
(IRS Employer Identification Number)</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding-right: 5.75pt; padding-left: 5.75pt; text-align: center">&nbsp;</TD>
    <TD STYLE="padding-right: 5.75pt; padding-left: 5.75pt; text-align: center">&nbsp;</TD>
    <TD STYLE="padding-right: 5.75pt; padding-left: 5.75pt; text-align: center">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding-right: 5.75pt; padding-left: 5.75pt; text-align: center"><B>12325 Emmet Street</B><BR>
<B>Omaha, NE</B><BR>
(Address of principal executive offices)</TD>
    <TD STYLE="padding-right: 5.75pt; padding-left: 5.75pt; text-align: center">&nbsp;</TD>
    <TD STYLE="padding-right: 5.75pt; padding-left: 5.75pt; text-align: center"><B>68164</B><BR>
(Zip Code)</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding-right: 5.75pt; padding-left: 5.75pt; text-align: center">&nbsp;</TD>
    <TD STYLE="padding-right: 5.75pt; padding-left: 5.75pt; text-align: center">&nbsp;</TD>
    <TD STYLE="padding-right: 5.75pt; padding-left: 5.75pt; text-align: center">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD COLSPAN="3" STYLE="padding-right: 5.75pt; padding-left: 5.75pt; text-align: center"><B>(402) 452-5400</B><BR>
(Registrant&rsquo;s telephone number, including area code)</TD></TR>
<TR STYLE="vertical-align: top">
    <TD COLSPAN="3" STYLE="padding-right: 5.75pt; padding-left: 5.75pt; text-align: center"><P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>
                                                                                <P STYLE="margin-top: 0; margin-bottom: 0"><B>Not applicable</B><BR> (Former name or former address, if changed since last report)</P></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Check the appropriate box below if the
Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Wingdings">&#168;</FONT>&#9;Written communications pursuant
to Rule 425 under the Securities Act (17 CFR 230.425)</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Wingdings">&#168;</FONT>&#9;Soliciting material pursuant to
Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Wingdings">&#168;</FONT>&#9;Pre-commencement communications
pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Wingdings">&#168;</FONT>&#9;Pre-commencement communications
pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e(c))</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<!-- Field: Page; Sequence: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font-size: 10pt"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0in"></TD><TD STYLE="width: 0.75in; text-align: left">Item 1.01. </TD><TD STYLE="text-align: justify">Entry into a Material Definitive Agreement.</TD>
</TR></TABLE>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On October 9, 2013 (the &ldquo;Effective
Date&rdquo;), Transgenomic, Inc. (&ldquo;Transgenomic&rdquo;) entered into a Collaboration Agreement (the &ldquo;Collaboration
Agreement&rdquo;) with PDI, Inc. a Delaware corporation d/b/a Interpace Diagnostics (&ldquo;Interpace&rdquo;). Pursuant to the
Collaboration Agreement, Transgenomic appointed Interpace as its exclusive marketer and promoter of Transgenomic&rsquo;s diagnostic
test, CardioPredict Pharmacogenomic Optimization Panel (&ldquo;CardioPredict&rdquo;), solely in the cardiology field in the United
States. A summary of certain terms of the Collaboration Agreement is set forth below.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Under the Collaboration Agreement, Interpace
will, among other things, provide sales representatives and ensure that a certain minimum number of units of CardioPredict in the
cardiology field in the United States will be sold through Interpace&rsquo;s efforts. Transgenomic will, among other things, provide
all specimen testing kits, conduct all specimen testing, and provide support to Interpace in its efforts, including reasonably
necessary product support to assist Interpace in its implementation and execution of the commercialization plans.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Collaboration Agreement provides that
the collaboration between the parties will consist of up to two phases. In phase one, Interpace will be required to, among other
things, implement a commercialization plan to market and promote CardioPredict in the cardiology field as a pilot program in the
United States for a specified period, subject to extension in certain circumstances. During this phase, Interpace and Transgenomic
will share profits according to ranges based on sales volume.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Interpace may, at any time during phase
one, notify Transgenomic that it elects to proceed to phase two; otherwise, after the expiration of phase one, Interpace may only
proceed to phase two if Transgenomic agrees in writing. During phase two, it is anticipated that Interpace will, among other things,
expand its infrastructure for more comprehensive marketing and promotional efforts for CardioPredict. During phase two, Interpace
and Transgenomic will share profits according to ranges based on sales volume.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Pursuant to the Collaboration Agreement,
Interpace also agreed, from time to time during phase two, to make certain loans to Transgenomic in such amounts as reasonably
requested by Transgenomic, subject to certain terms and conditions. Such loans would be made in the form of secured convertible
notes and would be convertible at any time at the option of Interpace into shares of common stock of Transgenomic at a conversion
rate of $0.75 per share, subject to adjustment in certain circumstances. The aggregate amount of such loans outstanding at any
time may not exceed $3,000,000, and the loans will be secured by a lien on Transgenomic&rsquo;s assets.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Pursuant to the Collaboration Agreement,
the parties have also agreed to discuss the possible commercialization of Transgenomic&rsquo;s diagnostic test, Clopidogrel Genetic
Absorption Activation Panel (&ldquo;C-GAAP&rdquo;). Transgenomic also agreed to provide certain first negotiation rights to Interpace
with respect to expanded commercialization of CardioPredict and other diagnostic tests inside the cardiology field in the United
States, provided, in each case, that Transgenomic will retain the right to carry out such commercialization activities itself.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Collaboration Agreement will expire
automatically upon the expiration of phase one unless Interpace elects to proceed to phase two, in which case the Collaboration
Agreement will expire ninety (90) days following the eighth (8th) year anniversary of the date that phase two began, subject to
an annual automatic renewal unless either party provides notice of non-renewal to the other party at least ninety (90) days prior
to the expiration of the current term. The parties also have certain termination rights upon the occurrence of, among other things,
a material uncured breach by the other party.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The foregoing description of the Collaboration
Agreement does not purport to be a complete description of all of the terms of the Collaboration Agreement and is qualified in
its entirety by reference to the full text of the Collaboration Agreement, a copy of which will be filed with the Securities and
Exchange Commission as an exhibit to Transgenomic&rsquo;s Quarterly Report on Form 10-Q for the quarter ended September 30, 2013
(the &ldquo;Form 10-Q&rdquo;) or Annual Report on Form 10-K for the year ending December 31, 2013 (the &ldquo;Form 10-K&rdquo;).
Certain terms of the Collaboration Agreement have been omitted from this Current Report on Form 8-K and will be omitted from the
version of the Collaboration Agreement to be attached as an exhibit to the Form 10-Q or Form 10-K, as applicable, pursuant to a
Confidential Treatment Request that Transgenomic plans to submit to the Securities and Exchange Commission at the time of the filing
of such Form 10-Q or Form 10-K.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<!-- Field: Page; Sequence: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font-size: 10pt"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0in"></TD><TD STYLE="width: 0.75in; text-align: left"><B>Item</B> 8.01. &#9;</TD><TD STYLE="text-align: justify"><B>Other Events.</B></TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On October 15, 2013, Transgenomic issued
the press release attached hereto as Exhibit 99.1 regarding the Collaboration Agreement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0in"></TD><TD STYLE="width: 0.75in; text-align: left">Item 9.01.&#9;</TD><TD STYLE="text-align: justify">Financial Statements and Exhibits.</TD>
</TR></TABLE>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0in"></TD><TD STYLE="width: 0.75in; text-align: center"><FONT STYLE="font-variant: normal">(d)</FONT></TD><TD STYLE="text-align: justify">Exhibits.</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0in"></TD><TD STYLE="width: 0.75in; text-align: center">99.1</TD><TD STYLE="text-align: justify">Press release issued by
                                                                      Transgenomic, Inc. on October 15, 2013.</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif"></P>

<!-- Field: Page; Sequence: 3 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font-size: 10pt"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>SIGNATURES</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Pursuant to the requirements
of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned
hereunto duly authorized.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 50%; padding: 0; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">October
    15, 2013</FONT></TD>
    <TD STYLE="width: 50%; padding: 0; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">TRANSGENOMIC,
    INC.</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding-right: 5.75pt; padding-left: 5.75pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="padding-right: 5.75pt; padding-left: 5.75pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding-right: 5.75pt; padding-left: 5.75pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="padding-right: 5.75pt; padding-left: 17.7pt; text-indent: -17.7pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">By&#9;<U>/s/
    Mark P. Colonnese&#9;</U><BR>
    Mark P. Colonnese<BR>
    Executive Vice President and Chief Financial Officer</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding-right: 5.75pt; padding-left: 5.75pt">&nbsp;</TD>
    <TD STYLE="padding-right: 5.75pt; padding-left: 17.7pt; text-indent: -17.7pt">&nbsp;</TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"></P>

<!-- Field: Page; Sequence: 4; Options: Last -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font-size: 10pt"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"></P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.1
<SEQUENCE>2
<FILENAME>v357358_ex99-1.htm
<DESCRIPTION>EXHIBIT 99.1
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="margin: 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0.25in 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0.25in 0pt 0"><B></B></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top; text-align: left">
    <TD STYLE="width: 50%">&nbsp;<IMG SRC="image_002.jpg" ALT=""></TD>
    <TD STYLE="width: 50%; text-align: center">&nbsp;<IMG SRC="image_004.jpg" ALT=""></TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0.25in 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0.25in 0pt 0; text-indent: 4.75in"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>PDI MEDIA AND INVESTOR CONTACT:</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Melody Carey</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Rx Communications Group, LLC</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">(917) 322-2571</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><U>mcarey@rxir.com</U></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>TRANSGENOMIC MEDIA AND INVESTOR CONTACT:</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Susan Kim</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Argot Partners</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">(212) 600-1902</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><U>susan@argotpartners.com</U></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>PDI, Inc. and Transgenomic, Inc. Partner
to Commercialize Personalized Medicine Molecular Diagnostic Test</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>- Companies enter long-term collaboration
advancing test designed for at-risk cardiac patients -</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>- PDI to host conference call today at
9:00AM ET -</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>PARSIPPANY, NJ and OMAHA, NE, October
15, 2013 &ndash;</B>PDI, Inc. (Nasdaq: PDII) and Transgenomic, Inc. (OTCBB: TBIO), today announced the signing of a U.S. collaboration
agreement to commercialize CardioPredict&trade;, a molecular diagnostic test developed by Transgenomic. CardioPredict&trade; is
a broad-based genetic assay which identifies a patient&rsquo;s specific genes that influence the effectiveness and safety of many
commonly used cardiovascular drugs.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The collaboration was formed to leverage
the fast-growing pharmacogenetic testing segment that has exhibited significant expansion over the last several years, particularly
in the cardiovascular therapeutic area. Pharmacogenetic tests identify genetic variations that affect drug effectiveness and, as
such, assist physicians with drug selection and dosing decisions. The CardioPredict&trade; personalized medicine test is well-positioned
as the most comprehensive assay that captures a specific set of genes known to influence each individual patient's ability to metabolize
commonly used cardiovascular drugs.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Under the terms of the strategic collaboration
agreement, PDI will be responsible for all U.S.-based marketing and promotion of CardioPredict&trade;, while Transgenomic will
be responsible for processing CardioPredict&trade; in its state-of-the-art CLIA lab and all customer support. Both parties will
bear the cost of their respective expenses and will split profit on a formula basis. In addition, PDI will provide Transgenomic
with funding support, principally to mitigate working capital requirements. Other financial terms of the collaboration were not
disclosed.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&quot;This collaboration with Transgenomic
is another step in our pursuit of commercialization opportunities for clinically valuable products aimed at adding more predictable,
higher growth, higher margin businesses that can leverage the substantial full commercialization capabilities of PDI,&rdquo; said
Nancy Lurker, chief executive officer of PDI, Inc. &ldquo;Transgenomic has strong scientific capabilities, an established, efficient
and effective CLIA lab and superior patient/physician support infrastructure.&rdquo;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<!-- Field: Page; Sequence: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font-size: 10pt"><TR><TD STYLE="text-align: right; width: 100%">Page <!-- Field: Sequence; Type: Arabic; Name: PageNo -->1<!-- Field: /Sequence --> of 3</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-size: 10pt; color: black">&ldquo;CardioPredict&trade;
is another example of our commitment to developing molecular diagnostics that support the advancement of personalized medicine,&rdquo;
said Paul Kinnon, president and chief executive officer of Transgenomic. &ldquo;This type of test panel has become a preferred
tool for cardiologists to personalize therapy selection for their patients with heart disease. When launched later this month,
we believe that CardioPredict&trade; will be the most comprehensive cardiology panel on the market. With an experienced sales team
and a demonstrated record of success in sales and marketing in the life sciences, PDI is the right partner for the launch and long-term
growth of CardioPredict&trade;.</FONT> <FONT STYLE="font-size: 10pt">We believe that strategic partnerships such as this one will
allow Transgenomic to globally commercialize our novel assays and clinical tests in order to more effectively address the expanding
genetics market.&quot;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Lurker continued, &ldquo;CardioPredict&trade;
provides an advanced personalized cardiovascular solution to patients who are taking one or more commonly prescribed cardiovascular
drugs in helping them and their physicians better assess how they individually metabolize and respond to these drugs. Relative
to higher-risk cardiovascular patients being treated within several critical drug classes: Antiarrythmic, Anticoagulants, Anti-thrombotics,
Statins and Beta-blockers, it is generally acknowledged that there are important genetic variants that significantly influence
drug absorption, activation or metabolism/elimination and should be considered when determining drug selection, dosing and monitoring.
CardioPredict&trade; represents a new personalized tool, with proprietary, patent pending features, to help assure that high-risk
cardiovascular patients get the appropriate drug regimen and doses for their unique personal genetic profile. We believe the clinical
value to patients is significant. There is a large market, a well-defined patient population and a clearly identified physician
base treating these patients that should allow for a very efficient use of PDI&rsquo;s broad base of commercialization capabilities.&rdquo;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><U>Conference Call</U></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Date: Today</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Time: 9:00 AM (ET)</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Dial-in numbers: (866) 644-4654 (U.S. and
Canada) or (706) 643-1203</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="color: black">Conference ID#:
</FONT>83167585</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Live webcast: <U>www.pdi-inc.com</U>,
under &quot;Investor Relations&quot;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="color: black">The teleconference
replay will be available three hours after completion through October 19, 2013 at (800) 585-8367 (U.S. and Canada) or (404) 537-3406.
The replay pass code is </FONT>83167585<FONT STYLE="color: black">. The archived web cast will be available for one year.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><U>About PDI, Inc.</U></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">PDI is a leading health care commercialization
company providing superior insight-driven, integrated multi-channel message delivery to established and emerging health care companies.
The company is dedicated to enhancing engagement with health care practitioners and optimizing commercial investments for its clients
by providing strategic flexibility, full product commercialization services, innovative multi-channel promotional solutions, and
sales and marketing expertise. For more information, please visit the company's website at <FONT STYLE="color: #17365D"><B>http://www.pdi-inc.com</B></FONT>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><U>About Transgenomic, Inc.</U></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="color: black">Transgenomic,
Inc. (</FONT><FONT STYLE="color: blue">www.transgenomic.com</FONT><FONT STYLE="color: black">) is a global biotechnology company
advancing personalized medicine in cardiology, oncology, and inherited diseases. The Company has three complementary business divisions:
Clinical Laboratories, Pharmacogenomic Services and Diagnostic Tools, which provide specialized diagnostic tests, contract research
services for drug development, and equipment, reagents and other consumables for clinical and research applications in molecular
testing and cytogenetics.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<!-- Field: Page; Sequence: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font-size: 10pt"><TR><TD STYLE="text-align: right; width: 100%">Page <!-- Field: Sequence; Type: Arabic; Name: PageNo -->2<!-- Field: /Sequence --> of 3</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><U>Forward-Looking Statements for PDI</U></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">This press release contains forward-looking
statements regarding future events and financial performance. These statements are based on current expectations and assumptions
involving judgments about, among other things, future economic, competitive and market conditions and future business decisions,
all of which are difficult or impossible to predict accurately and many of which are beyond PDI's control. These statements also
involve known and unknown risks, uncertainties and other factors that may cause PDI's actual results to be materially different
from those expressed or implied by any forward-looking statement. For example, with respect to statements regarding projections
of future revenues, growth and profitability, actual results may differ materially from those set forth in this release based on
the loss, early termination or significant reduction of any of our existing service contracts, the failure to meet performance
goals in PDI's incentive-based arrangements with customers, the inability to secure additional business or our inability to develop
more predictable, higher margin business through in-licensing or other means. Additionally, all forward-looking statements are
subject to the risk factors detailed from time to time in PDI's periodic filings with the Securities and Exchange Commission, including
without limitation, PDI's subsequently filed Annual Report on Form 10-K for the year ended December 31, 2012 and current reports
on Forms 10-Q and Forms 8-K. Because of these and other risks, uncertainties and assumptions, undue reliance should not be placed
on these forward-looking statements. In addition, these statements speak only as of the date of this press release and, except
as may be required by law, PDI undertakes no obligation to revise or update publicly any forward-looking statements for any reason.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><U>Forward-Looking Statements for Transgenomic</U></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Certain statements in this press release
constitute &ldquo;forward-looking statements&rdquo; of Transgenomic within the meaning of the Private Securities Litigation Reform
Act of 1995, which involve known and unknown risks, uncertainties and other factors that may cause actual results to be materially
different from any future results, performance or achievements expressed or implied by such statements. Forward-looking statements
include, but are not limited to, those with respect to management's current views and estimates of future economic circumstances,
industry conditions, company performance and financial results, including the ability of the Company to grow its involvement in
the diagnostic products and services markets. The known risks, uncertainties and other factors affecting these forward-looking
statements are described from time to time in Transgenomic's filings with the Securities and Exchange Commission. Any change in
such factors, risks and uncertainties may cause the actual results, events and performance to differ materially from those referred
to in such statements. Accordingly, the Company claims the protection of the safe harbor for forward-looking statements contained
in the Private Securities Litigation Reform Act of 1995 with respect to all statements contained in this press release. All information
in this press release is as of the date of the release and Transgenomic does not undertake any duty to update this information,
including any forward-looking statements, unless required by law.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0.25in 0pt 9pt; text-align: center">###</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0.25in 0pt 9pt; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0.25in 0pt 9pt; text-align: center"></P>

<!-- Field: Page; Sequence: 3; Options: Last -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font-size: 10pt"><TR><TD STYLE="text-align: right; width: 100%">Page <!-- Field: Sequence; Type: Arabic; Name: PageNo -->3<!-- Field: /Sequence --> of 3</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0.25in 0pt 9pt; text-align: center">&nbsp;</P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>3
<FILENAME>image_002.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 image_002.jpg
M_]C_X``02D9)1@`!`0$`>`!X``#_VP!#``@&!@<&!0@'!P<)"0@*#!0-#`L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+#`Q-#0T'R<Y/3@R/"XS-#+_
MVP!#`0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P``1"`!L`.`#`2(``A$!`Q$!_\0`
M'P```04!`0$!`0$```````````$"`P0%!@<("0H+_\0`M1```@$#`P($`P4%
M!`0```%]`0(#``01!1(A,4$&$U%A!R)Q%#*!D:$((T*QP152T?`D,V)R@@D*
M%A<8&1HE)B<H*2HT-38W.#DZ0T1%1D=(24I35%565UA96F-D969G:&EJ<W1U
M=G=X>7J#A(6&AXB)BI*3E)66EYB9FJ*CI*6FIZBIJK*SM+6VM[BYNL+#Q,7&
MQ\C)RM+3U-76U]C9VN'BX^3EYN?HZ>KQ\O/T]?;W^/GZ_\0`'P$``P$!`0$!
M`0$!`0````````$"`P0%!@<("0H+_\0`M1$``@$"!`0#!`<%!`0``0)W``$"
M`Q$$!2$Q!A)!40=A<1,B,H$(%$*1H;'!"2,S4O`58G+1"A8D-.$E\1<8&1HF
M)R@I*C4V-S@Y.D-$149'2$E*4U155E=865IC9&5F9VAI:G-T=79W>'EZ@H.$
MA8:'B(F*DI.4E9:7F)F:HJ.DI::GJ*FJLK.TM;:WN+FZPL/$Q<;'R,G*TM/4
MU=;7V-G:XN/DY>;GZ.GJ\O/T]?;W^/GZ_]H`#`,!``(1`Q$`/P#W^BBB@`HH
MHH`****`"BBFNZHI9F"J.230`XU#-<PVZYE<#V[UC7WB`#<EJ0%4?-*W05YU
MKGCPK,UOI`^TW&</</\`=4^WK712PTYLY*^,ITE=L]&U+Q/9:;"9;F:.WC'.
M9#R?H*XN^^+&7*Z78M,H_P"6LQV#\`*\\E6:\N#<WT[W,Y_B<Y`^@IVVO3I8
M""^/4\'$9U4EI2T.K;XE>(VD+![9%_NB+/ZUT?A[XE_:[N.TU:%(BY"K.AXS
M[CM7F.VE"\C'7(K:>#HRC;EL<E/,\3"?,Y7\F?2(.>1TI:J::7.F6ID^^8ES
M^56Z^?:L['V:=U<****0PHHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`*3
M-+6?JNK6^DV_F3-ES]Q!U8TTG)V0I245=[$]Y>P6,!FN'"J.@[GZ5Q.L^(O-
MB>>YE$%FG.W/7_$UEZOKAD#W^H2[8T^ZHZ#V'O7"WEW<Z]<":XREHI_=0_U-
M>EA\)KKN>+C,Q48^1/JVNW>ODPP[K?3@>`.&D^M5(X4A0)&H515B.)G98XT+
M,>%51DUV&C?#O4+X++?.+2$\[>KD?3M7HN5.A'WG8\!+$8Z?N*_Y'$[:-M>H
M-X*T2&5HO+EDV\%B^#7"ZYIL>EZO/:1/O1#\I/4#T-*EB857:(8K`5L-#GG:
MWD9.VM#1-.?4]:M+15)\R0;L=AW-5-M>C?#;12BS:M*GWOW<.?3N:>(J^RIN
M1.`H/$5XPZ;OT/0E4(BJ.BC`IU)BEKYL^\"BBB@`HHHH`****`"BBB@`HHHH
M`****`"BBB@`HH-9VLZQ;:)I[W=P>!PB#JQ]!3C%R=EN3.<81<I.R0W6M:M]
M%M/-F.Z1N(XQU8UYIJ&JR7,DM_?S<`9]E'H*JW>J7&KWSWEV_)^ZN>(U]!6&
M0_B*]V(2NG6[?,?^>C5Z]'#JDM=SYZOC77?N[=/\V1DS^(+H74P*6,9Q%$?X
MO<ULZ?HESJEV+:SCW-W./E4>]:NDZ'+J=RMM;($C7[S8X05Z9I>E6NDVBP6R
M8_O.>K'U-%;%*DK1W%0RYXF7-4V_K8S/#_A.QT.-9-@FNR/FE8=/IZ5MW$P@
M@>1NPJ6L+5;SSIA`ARJ'YL=S7F7E5G>3N>]&$*$.6"LBE/>1V=K/>W!_=Q*9
M']_:O,F\R^DDO)_]9.QD/L#T'Y5T'BG4&OKV+0[=OW<>);MA_P".I5$Q>@]@
M*]/#QY%S=6>'CW[:7)T7YE;3=&DU34(K.$<N?F/]U>YKVBSM8K&TBMH5Q'$H
M45A^$]#&F6?VB9?])F&3_LKZ5T=<6+K^TE9;(]#+L&L/#FMJPHHHKD/2"BBB
M@`HHHH`****`"BBB@`HHHH`****`"BBD/%`$-W=PV-I+=7#A(HUW,QKQ?Q#X
MAG\0:F9F)6W0XBC]!Z_6M7QWXG.IWK:;:R?Z'"?G*G_6-_@*XR2<6\32XR1]
MT>IKVL%AO9Q]I+=GR>;8]UI^PI/W5OYLGN#/?7$>E6AP\@S,X_@6NOTC1`YA
MT^S3"@<MCIZDU2\/:,UC9AY`6O+HAI/;/1:]0T72ETRTY`,TG+M_2L\1B%%:
M';@L&Y6YBQING0:99K;PKP/O-W8^IJY29JEJ6I1:=!N8AI#]Q/6O+UD_,]WW
M81[)$>K:B+.'RT/[Y^@]!ZUQ6N:TNBZ=YH&^[F.R"/NS'O\`05-?:FD$4VH7
MTN$498G^0KF=-ANM7O3KFHIM)&VTA/\`RS3U^M=U*DHK4\VO7<G:._Y#M.T]
M[2W)G?S+J9O,GD/4L:Z[PQH?VF<7UPO[E#\BD?>/K4.D:.^I7(W#$"'+MZ^U
M=U'$D42QQJ%11@`4L17LN5;AA<*F^:6R'5C>)/$4/ANRCNIH7E5WV84XK:Q7
M!_%3_D`6W_7:N;#P4ZJB]CKQ=25*A*<=TB'_`(6O8?\`0/G_`.^A1_PMC3_^
M?"?_`+Z%<?X$M+2]\2I#>Q1RPF-CMDZ9KU7_`(1KPW_T#[+\A7;7AAJ,N5Q;
M/,PM7&XFGSQFE\CFO^%L:?\`\^$__?0I1\5]/)YL)P/]X5TG_"->&_\`H'V7
MY"N%^(^DZ1IUO9R:?##%,[D.L1ZKCTJ:2PU2:@HO4O$2QM"FZCFG;R.^T#Q/
MIWB*)VLG8/'C?&XP1_\`6K6GE$$$DI&0BEB![#->2?"PD>(+@9X,/]:]6O\`
M_D'77_7)_P"1KGQ-&-*KR+8[,%B)5\/[26^IPQ^*UB&(_L^?@X^\*3_A;%A_
MSX3_`/?0KRMO]<W^]_6O<-/\(Z#+IUM(^FP%FC4DXZG%=M>CAZ*3E%ZGF83$
MXS%.2C)*WD8?_"V+#_GPG_[Z%30_%327;$MK<(/4#-;_`/PAOA__`*!D'Y55
MO?`'AZ[B*BT\EL<-$V,5S<^$?V6=KIY@E=3B_D7-*\6:-K)"6MXOFG_EG)\K
M?E6U7@?B70)O#.L?9O-+H1OBE'!(_P`:]'^'?B.?6-/EL[MB]Q:XPY/+J>F?
M>G7PD8P]K3=T3A,PE.JZ%96D=A=7`M;2:X8$K$A<@=P!FN#'Q7L/^@?/_P!]
M"NUUC_D"WW_7N_\`Z":^=!58+#TZJ;FC/-,;5P\HJF]SZ8S7'^/?$G]D:;]C
MMWQ>7(QQU1.YKJ;NZCLK.6YF(6.)2S'Z5X)K.K3:WJT]]*3\[?(O]U>PJ,#0
M]I/F>R-,VQGL*7+'XI?D4UK0T.P&IZ]&D@S#:KYKCU/:L]:Z;P=+!%=7<4C!
M9)@"A;C..U>Q7;5-V/F,!&,L1%2/0/#^GB6X:ZD'"'"_6NGK/MY[/3M/C$MQ
M$BA<DEAUK`U3QFAW0Z8-QZ&9AP/H*\%PG5EHC[/VE.A#WF;FK:U!ID97(><C
MY8Q_,UQ=WJ!<RWM[,%51EF)X4>@K/GNUC62[NYL`<O(YK)M+.Z\8W2R3*\&B
M1-\J]#,:ZZ=&--79P5<3*J[17HO\QUO%/XNOENKA&CT>W;]S&?\`ELWJ?:NT
ML=-DOIQ&@Q&/O-V458L-+\[9!`@CAC`'`X45U-M;16L(CB7`'4^M95:]M$;T
M,-UD+;6T=I`L,2X1?UJ:BBN)NYZ*5M$&:X/XJ?\`(`MO^NU=X:XCXF6MQ=Z'
M;I;P22L)N0BY-=&%=JT3DQZ;PTTNQYEH&DW.M:HMG:3"*4J6W$D<"NL_X5MK
MW_037_OMJK_#[3+^U\51R3V<\2"-OF="!7L%=V+Q4Z=2T-CRLNP%*K1YJB=[
M^AY/_P`*VU__`*":_P#?;4QOA?K,K`R7T+>[$FO6Z*Y?KU;R^X[GE6&>Z?WL
MY7PAX,3PR99Y+CS[F4!2P&`H]JZ*_P#^0==?]<G_`)&K%07JEK"X51DF)@!Z
M\&N>5252?-)ZG9"C"E3Y(*R/G!O]<W^__6OHO2_^05:?]<E_E7@3:)JID8C3
MKG[Q_P"69]:Z.+Q!XVAB2)(K@(@"@>1VKU\72]LDHM:'SF6XA89R<XO7LCV6
MD)P,G@5X[_PD?C@_P7'_`'XJM.WC?5@8Y!?LC<%!\HKB6!?VI(]1YK%_!"3?
MH3_$K5;;4=>ABMI%D%M'L=E.1NSG%:OPHLY?/O[TJ1%@1J>Q/>LW1OAKJM[,
MKZABT@S\P)RY'M7JVF:9:Z181V=G'LAC''J3ZGWK;$5J<*/L8.YRX+#5JN)>
M*JKE\A-8_P"0+??]>[_^@FOG05]&:JC2:1>HBEF:!P`.I.#7@0T35?\`H'7/
M_?LU66R2C*Y&=PE*<++HSTGXGZPUOI\&EQ,0UP=TF/[H[?G7EJUT/CR]-YXO
MNP3\L!$0'IBN>%=F$I\E)(\O,ZSJXB3Z+3[B1:E3[PQUJ):F3J*Z#S&:L!+X
MW,S_`.\Q-6+B]M]/MC-</M4=%'5O85DMJ/ERI:VD375X_"1(,\^]=?X?\".)
MUU+Q"1<7><QVV<I']?4UQ5JD8?$>]A*,ZBM%?,R-)\/WWB>6.^U96M]+4[HK
M;H9/K[5Z-8Z6'1(XT$5N@P`HP`/05H16(QYDWRHHSM]JR(/'>CNZ)Y=U%`S^
M6L[Q8CSG'6O.G4J5;\JV/;A3HX>RF]7WZG30PI!&(XUPHJ2F>8@`^=1D9Y-!
MD48RZC/3FN/4]`226.(`R.J`\98XIOVRV_Y^(O\`OL5!J&G6.HQ(E_"DJ(<J
M'.`#5`>%?#Y!8:?`0.IR<?SJXJ%M6_Z^9E)U;^ZE;U_X!K?;+;_GXB_[[%'V
MRV_Y^(O^^Q62OA3P^RY73H"/4$G^M`\*^'V)`T^`D=@3_C56I]W]W_!)YJ_9
M?>_\C6^V6W_/Q%_WV*/MEM_S\1?]]BLK_A$]`)Q_9L.?3)_QH'A30#D#3H3C
MKR?\:+4^[^[_`((7K]E][_R-7[9;?\_$7_?8H^V6W_/Q%_WV*RO^$3T`YQIL
M)(Z\G_&C_A%-`P3_`&=!@>Y_QHM3[O[O^"%Z_9?>_P#(U?MEM_S\1?\`?8H^
MV6W_`#\1?]]BLH^%-`"[CIT(7U)./YTT>%O#VW=]@M]OKN./YT6I]W]W_!#F
MK]E][_R-?[9;?\_$7_?8H^V6W_/Q%_WV*R5\*>'V'RZ=`?H2?ZUAZHOA/2M0
M-B^C23W`3S&6",MM7WYJHTX3=HW^[_@D5*U2FN::27J_\CLOMEM_S\1?]]BC
M[9;?\_$7_?8KGM-T?PMJUDMW9V,+Q$X.<@J>X(SP:MKX4\/MRNG0'Z$_XU+C
M33L[_=_P2HSK25TE;U?^1K?;+;_GXB_[[%'VRV_Y^(O^^Q62/"GA\G_D'0?F
M?\:4^%-`!P=-@!],G_&BU/N_N_X(^:OV7WO_`"-7[9;?\_$7_?8H^V6W_/Q%
M_P!]BLD>%O#S'"Z?;D^@8_XTO_"*>'\;O[.@QZY/^-%J?=_=_P`$.:OV7WO_
M`"/+/'FDSZ=XGN9W4F"Z<R(^..>HKFUKZ)O;"UU&V,%Y`DT3=5<9KFI?AOX>
MEDW>5.@_NI+@?RKTJ&/CR*,EJCPL9D\G4<Z<E9]SQMYXX?OMR>BCDG\*W]&\
M&Z[X@PXC.G61ZS3##,/85ZSIOA/0](.ZTTZ%9,?ZQAN8_B:V,#CBLZN8MZ05
MC;#9'"#YJKN<WX?\(:;X>AVV4.Z<CY[F3EV_PKH(K=(^<9;U-2TM>=*<I.[9
M[<*<8*T49/B:[-CX;OYU.&$1"_4\"N6LM$UO4M`L-'N+6"SL$V/++OW/(`<X
M`[9KLM5TRWU>R-I=!C$S!B%.,X.:MA0J!1P`,"M85>2%DM;G/4H>UJWD]+6M
MW[W_``/.[.V_MSQ%J$LFG7-U9K.+='6X\M8@HP>,\U5UZ]MV\37D,MM=3PPH
MEI`8YBB1R8.-QKK+7P;86EV+F"YOD)E\TH)_E+9SR,59D\,Z=)97]NRR%;V3
MS96W?,&]0>U=7M8QEY6M_6IP*A.=-[7NV_Q\OSN<GJD&H1G0-#N!-?SHC37"
M12["PZ`%O:K?V1;KQ!:^'HUFM;&.#[5<1"4EG8]%+9SBNK@T>UAU);\&1KA8
M!`"S9^4?UJKJ_A^TU"Z2^+SP72+Y?FP2;6*^AK-5;M1_J[-I8=QBY[ZK[E;2
M^_J<Y9SC1]9\1Q6<LG]G6MIN"LY8)+CL365X:BGO-1L!!'<VMU:XGOYIICB5
M#R`%ST-=P/"VF#19=+"R""<AI7W_`#N<YR6[U+-H%E)>170\Q)8[<VX*-C*$
M8P?6J]M&S75_HB7AIMQ=]%K;U=]--+:?CL<+:Z[-;:_=:S)+(T5['*EI"3P2
M&"K@?6K6AZG+X?T77+^^F::X6<(`QS^\(SM'T)KJT\+:8KZ:WENQTY2(,MGK
MW/K4<7A33(KM9MLKE)FN-COE3(W<CO3=6FU:W](F-"O%IJ6OSW:5W][.8\):
MH(+_`%4-?M=,UJ+EV).%<`D@`]AQ63%?ZA:Z7<V$T\ADU?9-;/N.1N;#`5Z'
M>>&=.N[N:Z9'CDE@-N_E-M!0_AUI9O#6FW#:<TD;9T_'D8;TZ9]:%7A?FMO;
M\`>%J\O)S;7[]68GD-KOB.32)YI%L--@0/&CE3*Y'4D=JI>(K)+2_P!)T/3[
M:XFA+/<20I.06'3&XG@5T>J^&K*^OA?"2XM[EAY;O;R;"Z^_'-1WOA&PO9X)
M7N+V.2"(1(\<V#M]SBIA-7B^EMO/N55INTDUK??ROMMV+VAV$-AIZB*UDMC(
M=[Q22ERI^M8N@NDWB3Q#JLI"QQ.(%<GC:HYKI+&T2RLH[9'D=4&`TC;F/U-8
M/_"#:4TKL\MXT<DAD>$S_(Q/7(Q64+-SYF=%6\53Y5MT^7IYG*K+<6W@W5;J
MWW`ZG?D6X7@LI.,CZU<\/G:][JUHD]G8VML\4L4TQ9GE`ZD=J[2ZT.QNOL*O
M&52RD$D*(<*".F15:7PUI\KZD#YJKJ`7SPKX!([CT-;>WC)-6W_X;\CF^JSA
M).^R_&S?;O\`@<@C3Z7HGAG4+B>3FX+3N6.-K\\_2GZC=7%UI&J^(G>1!<#[
M)81AL83.-WU/-=CJ.@6&I:1'IEPC?9H]H4*V#A>G-)JF@66JZ;%I\PDCMXB&
M01-MQCI2C6BVFUK?\+W*GAIQC))Z)+[[6_KS.<L[2/1=`O=1FT^XL[J&W*AY
M;CS-Y(Z@9XYK!MI[U;2#PS<S3>?<7,4J2;CDQL,GFNX7PI9?V=<6,MQ>30SL
MI?S9MQX.<`XZ5;DT"PEU:TU)HV^T6L?EQD'C;[BG[91;OJ_\MB?J\IJ/*[+;
'[WKLEY'_V3\_
`
end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>4
<FILENAME>image_004.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 image_004.jpg
M_]C_X``02D9)1@`!`0$`>`!X``#_VP!#``@&!@<&!0@'!P<)"0@*#!0-#`L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+#`Q-#0T'R<Y/3@R/"XS-#+_
MVP!#`0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P``1"`!:`50#`2(``A$!`Q$!_\0`
M'P```04!`0$!`0$```````````$"`P0%!@<("0H+_\0`M1```@$#`P($`P4%
M!`0```%]`0(#``01!1(A,4$&$U%A!R)Q%#*!D:$((T*QP152T?`D,V)R@@D*
M%A<8&1HE)B<H*2HT-38W.#DZ0T1%1D=(24I35%565UA96F-D969G:&EJ<W1U
M=G=X>7J#A(6&AXB)BI*3E)66EYB9FJ*CI*6FIZBIJK*SM+6VM[BYNL+#Q,7&
MQ\C)RM+3U-76U]C9VN'BX^3EYN?HZ>KQ\O/T]?;W^/GZ_\0`'P$``P$!`0$!
M`0$!`0````````$"`P0%!@<("0H+_\0`M1$``@$"!`0#!`<%!`0``0)W``$"
M`Q$$!2$Q!A)!40=A<1,B,H$(%$*1H;'!"2,S4O`58G+1"A8D-.$E\1<8&1HF
M)R@I*C4V-S@Y.D-$149'2$E*4U155E=865IC9&5F9VAI:G-T=79W>'EZ@H.$
MA8:'B(F*DI.4E9:7F)F:HJ.DI::GJ*FJLK.TM;:WN+FZPL/$Q<;'R,G*TM/4
MU=;7V-G:XN/DY>;GZ.GJ\O/T]?;W^/GZ_]H`#`,!``(1`Q$`/P#W[M1Z4=J/
M2@`[T=Z.]'>@#F_&.KKI^E&W4%I;D%!@_=]ZM^%[";3M"BAGDWL?G'L#VKG;
M*--:\=W$TBN([?HCC()%=M=7,-E:27-PXCAB4L['H`*ZJON05);O5G'1O4J.
MJ]EHATLL<$1DE=4C49+,<`412QSQK)$ZNC#(93D&O%_$WBC4O'NL#P]H66TF
M9E5KA4/7N2>PKT_PCH#>&?#MOI;W#7#1Y)<^_85%2A[."<GJ^AU)W9N=Z.U'
M>CM6!0=J/2CM1Z4`'>CO1WH[T`':CM1VH[4`'I1WH]*.]`!WH[4=Z.U`!VH]
M*.U'I0`=Z.]'>CO0`=J.U':CM0`>E'>CTH[T`'>CM1WH[4`':CTH[4>E`!WH
M[T=Z.]`!VH[4=J.U`!Z4=Z/2CO0`=Z.U'>CM0`=J/2CM1Z4`!HH-%`!VH]*.
MU'I0`=Z;(VV-V)P`I.?2G=ZYGQEXRL/"5@KW6YYILK&B\\XZGVJH1<Y*,5J)
M[&+X;U:TTZ75KZ]OD"[B0'."^/2N-O-8U[XHZL(='66WTN$B.X3?@$$]3Z\5
MG>'_``EJ/CN]F;4;P6J1OYJ)CEP3DX_"O:8H-#\'Z7N_<64'`>0C&X^_J:]*
MM*%*;<5>3_`YL/!JFHMC/"WA33_"6GM:6`8AVWN[G))K=[USG_">>&/^@Q;_
M`)T?\)[X8_Z#%O\`G7!*%63O).YTW1T?>CM5:PU&TU2U6ZLKA)X6X#H<BK/:
MLFFM&,.U'I1VH]*`#O1WH[T=Z`#M1VH[4=J`#TH[T>E'>@`[T=J.]':@`[4>
ME':CTH`.]'>CO1WH`.U':CM1VH`/2CO1Z4=Z`#O1VH[T=J`#M1Z4=J/2@`[T
M=Z"0`23@#K6=IVNZ7JT\\-A>Q3R0'$BH>5II-JX&CVH[44=J0!Z4=ZANKJ"R
MMVGN)5CB7JS&J5CX@T[4+@00S,)",JLB%=WTSUIJ+:ND!I]Z.U'>CM2`.U'I
M1VH]*``T4&B@`XQ1QQ1VHH`PO%OB:W\*Z'+J,J>:ZX"1!L%B:\7M-*UK67;Q
M?=:<VJZ;)*S&U:0[E&>P]JT/%#3>/_B,VG:<[1-9(5"S'Y'9?;MFN\\-^+&M
M+Q/#NMZ:--NT4",H/W4H]0:]*$70I^ZKR>_H9MIO78R_"VK65WXIBN-.LV@@
MF39Y<G!C..:[/Q1X8L?%>E"PORZQAPZLAY!KF]=ACL/&UA-!`JK(03C@,:[[
M/%8XB5G"I#30Y\+HYP?1GA'C_P"&VD^%/#PU"SFGDE\P)B3&,&I/`GPRTCQ1
MX9CU*[GG29I&4A,8P*Z_XS_\B2/^NZU/\'O^1!A_Z[/_`$K?V]3ZMSWUN='*
MN:Q=A?P[\,-"@M);AXX))"%+#<S,:EO_`(C^&--O4M)[\>8X#9120`>F37%?
M'4XMM*/H[?RJ_P"%/AAH.H>$K2XU*W::[N4$CR;N1Z`5E[.G[-5:K=V.[O9'
M>7_B/2-,TQ-1N[V)+60;HWSG>/8=ZYE/B]X2>;R_M<H&<;C$<5E>-/!%A-?:
M1)>:K#9:)91B,P2-@D#T^M8_BK6?A\^@7&G:;9K+<A,1/!$?E(Z$M12H4I):
M-W[=`;9Z_8ZA::E9I>6<Z36[C*NIXK&M?'/AZ[FOXTOT4V.?.+\`?3UKBO@G
M/*_AG4X&8E(Y,J/3(.:X?P=X?@\2?$"[LKLM]E61Y)44XW@'@&A86"E-2?PA
MS/0]?LOB=X5O[Y;2+4,.QVJSJ0I/UKK)9X8+=IY9%2)5W,['``]:\2^+GA+2
M=!L]/O=+M5MB[E'5.AP.#71:W#JNM_!>T^Q^9)<&!&D"GYG4=:4J%-J$H.R;
MMJ"D]4S9G^*_A*"Y,)OV8@X++&2/SKJ-*UG3];M!=:==)/%W*GD?4=J\1\(^
M*/"%CH@T;7M'\N;E9)C'DMG]17=?#?P]I.DRZA?Z/K`O;2?[L0X\L>X]:=?#
MPA%Z--?<P4FSJ->\5Z-X:16U.[6)F^Z@Y8_A5+2OB#X;U>&>2VOU'DH7=7&T
MX'H.]>265G_PG?Q9N8]19GMXY&RN?X%Z`5VOQ`\!:-#X6N+_`$RT6SNK1-P:
M(D;E[@T.A2@XPFWS/[@YF]4=QH'B+3?$M@UYIDIDB5RAR,$$5FZY\0/#GA^X
M-O>7P,Z]4C&XCZXKSOX=ZF^C_##Q!?Q<21,2OL2,?UK"^'UWX5AFO-1\43++
M>._[M95+#GJU5]4BI3;NTNVXN9Z'L^@>-]!\2R>5I]X&F`_U;C:Q^@/6K>O^
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M>M<[:^/_``W=0WLJ:@JI9MME+C'MQZUQ'PAUNXN_#FK:7.[.MJC-$2<X4CI7
M(?#CP]:>(O&%S!?IYEK#OD:+/#'/&:I86,>?G?PAS/2Q[#I/Q&\,ZU?"SM;[
M$S?=$B[0WT)IFH?$SPMIM^UG-?[I5.&,:E@I^M>2?%'0+'0O%=K%I<0MDGC!
MVH?NMG&178>)O`&AZ9\.)+F*V'VZ.)93<$_,S'&<U3P]!<LKNTA<TM3TZVOK
M+5--^U6TZ2VLJ'YU/&,<UP_P\L/"=KK&JOH%Y+/<EL2K(,;1GMZC-9?P=GDD
M\$ZI$S$I&S[1Z94UC?!7_D:M7_ZY?^S5/L>2-6*>UAWO8]=UKQ#I7AZV$^IW
M:0*?N@\LWT%<[8_%7PI?7(MUOFC8G`:1"!^=>;W$3>/OBX]E>.QLX9&4)GHB
M]0/K7H/B;X7:)JFBO!IMG%:7D:_N9%[GT-)T:-/EC4;N_P``NWL:'C)TDM+*
M9COLSO)93E=Q7Y"?QKF;&UN;8B"Y?=?2/$UH(V+#J<G)Z<=:ZOP7H%]I/A*'
M2]:=+F1<@K]X!>PK8LM%T[3Y3):VJ(Y_BY)'TSTK/VJ@G!:CM?4OCWZT<8HH
M[5RE!QBCCBCM1Z4`!Q10:*`#M69XBOETWP]?733BW*0MMD/\+8XK3[5Q7Q5N
M9K?P+="*V$RR$(^?X!ZUI2CS34?,3V."^'.N-H<D^J:M:/<07\NU=01=Q1L]
M&],U[#=66G:]9C>(YD(^61>J_0]JY#X73Z1<>$(],2)4N$R;BWEY))_BQZ5<
MUF+_`(11_M>F7*QHY^>T8Y!]Q775_>5FHZ2Z?UT.>I+DA>2O'J8&H6DO_"3V
MNG?;&NA$ZJI)Y4>F:]24;4`]!BO.O"&G3:KK;ZK<J6C1BP8GJ]>C=JG&RUC#
MLOQ,<!'W93MN]/0\[^,X/_"$`]A.N:G^#^?^$!AX_P"6S_TKL]2TRSU>R>SO
MX$GMW^\C#BET_3K72[..SLH5AMXQA44<"LO;+V'LNM[G;;6YY1\=N+32O]]O
MY5Z3X4&/"FE\8_T=?Y5/JVA:;KL*0ZE:1W"1MN4..AJ]%$D,2Q1J%1`%51T`
MI3K*5*-/L"6MSP;XGR/_`,+'MUU?S#I:A"%'W2O?%=%K_B/PA:^&;C3_``W:
MPW%Y<Q%$2WBR5!'))[5Z1JV@Z7KD`BU*SBN%7[N\<CZ&H-)\*Z'HA)T_38(6
M88+!<DBMOK,'"*:=U]PN5W/-?@C<H-/UFS/^M4AB/P-9?PKS_P`++U3CHLF?
M^^J]ETW0-+T>:XEL+.*![AMTI0?>-)8>'M*TR_N+VSLHH;FX.9)%'+42Q46Y
MM+X@47H>>?'/_D7].]///\JM-K&K:%\'],OM(A$DZ1)OW+G:O<XKO=5T73]<
MM!;:E;)<0A@P5QT-6(K2WAM%M8XD6W5=@CQP!Z5FJ\53C!J]G<?+K<\N@\2^
M`?%.BB?78;:"]V8F4KM;=ZK6#\(K>4^-K^33_-_LI48$L.",_+GWKT^X^'OA
M6YN#/)H]OO)R<#`-;FGZ99:5;BWL+:.WB'\,:XK1XB"A*,+Z]]D+E=]3PN]>
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M;@KCH:R5>G&I&44[+[Q\KL9_@K/_``A.E?\`7N*\F\`Y_P"%PWX]&ES^=>ZP
M01VT"0PH$BC7:J@<`5GVGA[2K'5)]3MK**.\G_UDH')J(5U'GT^(;6QXWXNM
M[KP3\3XO$'D,]E-()`P''/WA]:ZGQ/\`%?0I/#4\>FS/->7$91$VXVY]:]&O
M;"TU&V-O>V\<\+=4=<BL.U\`>%[.Y$\6CVXD!R"1G%:*O2DHNHG=?B+E:V.-
M^$_AZYTWPQJ6I74;1O>(WEJPP=H'6L+X,Y_X3#5>.B-_Z$:]R"*%V!0%`P%`
MXQ6=IGA[2M'N+B>PLHX);@YD91RU)XKF4[K60<NQX]\9<_\`"9:5QU1?_0A7
MHGC@'_A6MYQ_R[+_`"%;FI>'M*UBXM[B_LHYY;<YC9ARM7KFU@N[5[:XC62"
M1=K(PX(]*EXA.,%;X1\NYY1\&LGP=JYQQN;_`-!-9?P5S_PE.K_]<O\`V:O8
M=+T73]%LS9Z?:I!`2244=2:9IGA_2M&GN)M/LXX)+AMTC*/O&KGB8OVFGQ"4
M=CQ34S/\/OBHVISPNUE-(6#`?>1NOXBNQ\2_%S1X=$D_L6=I[^5<1C;]PGN:
M]!U'2K#5K<P:A:Q7$?\`=D7.*Q[/P%X8L+@3P:1;B0'()7.*/;TIV=1.Z_$.
M5K8K?#JYUJ\\)PW&N.SW$C%D+C#;>V:ZSO0%"@```#H!1WKDG+FDY6L4M$'>
MCM1WH[5(P[4>E':CTH`#10:*`#M7!_%Z)7\#2LUP\6R12`HSO/H:[F6:*"/?
M+(J+ZL<5YOXN\51ZC;W.G"V5H$;._P"\3CT%=.$IRE432V,*]>%*.NY1T:?0
MXO"6G7EO<R+K$=N%64##$C^%O:KVGZ9J'C"[^V7<FQ8BJ,2N-P]JJ^`],T[Q
M+$]TOFHMI-MQMPKUZFD:1#:B!5]`,5U5ZRHMQAK+OV.2-"=>7/5TCV[^I%9V
M=O86RP6T8CC7H!4_:CM1VKS6VW=GHI)*R,_6-7M]%LA<W`8@G:%7J35FRNXK
M^SBNH3F.1<BN0U_4;2?Q3;VMVQ^R6REG`&<L:@T;6_L.C:M!`VXVY,D!(_A-
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MY',2J?3UI_5URIW_`*N3]:?,U;^K7.]Q1BN$M[^^UV?2[![IX4>$R2NAPSD5
MH:8;NU\8R6$MY)/"D&4#'^?O4RP[BG=ZK4J.*4FK+1NQ:\0:EI27$=A?Z>;U
MW7<$\L-Q5+0H/"T]^T5KHT-K=H-P5X0#]146MS7$'CBTDM(!/,(3A"<9JMJ(
MU:WGG\074$=M)''Y42*<G)[FMXTER))VNN_7T,95YJ;?1/MT]3O,`#%&*X&&
MYO(/L=S:37TUP[KYRRCY&!ZXJ?3K>_UF]U+.HS0K!,?+53T/O[5D\-9-N6AJ
ML7=I*.K.WQS17GR3W5LX_M&ZO+:\\WB?.Z)AFM.(W'B+6KR$WLL-M;`!!"<;
MCZTGAK:MZ!'%<VB6O8Z[%&.*\[N-6U);467VIO.M[P1B8=6'O6HPN]&\2VD/
MV^6:.ZC8OYIX!`ZTWAFNO?\``%BT]EII^)V&*S9M:@AU.2P*.TJ0F7Y1U'I7
M'7ES(MC->17]Y/=(V?,CXB'/2K$MU+)K;W6[$ITS=N'KBJCAK:MD2Q=]$O\`
MACM+*Y%Y:QW`C>,.,[7&"*GQ7"F4CPW:WT^H70N'3;'%&W+M3+J?5=)TNRMK
MFZF,U[)EV'+(OH/>I^K7>CZE?6[+5=+G>XXJMJ%['IUC+=R@E(QD@=:XT:C>
M:5<2O:&[FM/));[0/NMZBHKRQNSX0?4Y-1EDDF4-(C'*D$]!3CAM5S/1BEBV
MXOE6J3.T?4H8]*_M%@WDB/S,=\56TK7[/5K*:[AW*D6=X8<CC-4;TX\!M_U[
M"N3AN6TBTN+9>/MULAC_`-X\&G3P\9Q=M[BJXF5.4;[6.XT;Q#9ZV\R6RN#%
MUW#K6OCBO-K2>3P^FK?9QB5$C0'T)[U<BN;NU:SN+.6^GF9AYZ2CY&!ZXIU,
M*KW@].GW"IXM\J4UKU^^QWC$*A8]`,UD6WB&WNXX)(H)F6:4Q9"_=([FL*PB
MO=<74-0>_FA:)V6*-3\J@>HK-TN[GM['21'*RA[M]X'\5*.&5FF[M?Y,<L5*
MZ:5D_P#-(]'QS526^6&_AM#%(S2@D.!\HQZUS%A;WOB/[9>MJ,T!20I"D9P%
MQZT7%WJ$&JZ;#-=!W^SOO,9^5B.]0J&MKZEO$OE4K:/_`#.RQQ1BO/HDU"?P
MI)JS:E.)8&;RU!XP#WJ:XUB?4=0MK6>6XC@6W5W^SCYG8BG]5=]'MN+ZXK*Z
MWM;YG=D45P":QKMD7@MHI9X%8^6\R_-CWHH^J3Z-?>'UV'5/[C/UG6I_%=Y#
M86L.Q=WR`G[Q]ZZ;3O"4%EI+&14_M`Q,/-/(4D>E5]*AB7QE<;8D&`<84<5V
M#\HP/3!K7$57!*G#1&6%I*<G5J:NYY)\&KGR;W6M.DO1(Z2EEC`XZG+"O7.<
MUY%\*XT7QCXA(100Y`P.G->N]ZRQG\9_([X;!SBBCM1VKE*,G3M"AL;F[N'/
MGR7#[B77[H]*CNO#5M<ZH;S.Q'B,4D2C`85M>E'>M/:SO>YE[&G;EMH<L_@Y
MY;)K.74YFMU/[I,?=^OK5W5?#4&J0V:/*R&VP-P'WE]*W.]':J]O4NG<GZM2
MLU;<Q=0T#[3>V][:7+6T\";`0N1M^E59/"2N]V[7LC-=1A9"P[^M=)VH]*2K
MU$K)C>'IMW:,B]T%+S3;2R,S*+9E8-CKBJ]QX;D%[-<Z??26AG'[U0,@^];_
M`'H[T*M-=1NA3>Z,!/"L$8L=D[YMI#(2>2Y-6++04L]-N[,3,PN&9BV.F:U^
MU':AUIM6;!4*:=TCB=2TZWTHZ=`SW$30(0M[&N<>Q%/\.6YF\37-[$TTL`BV
MF:48+M[5V1577#*"/0C-`54`"@`>@&*T>(;@T]V8K#)5$ULC-FT9)=?AU4RD
M-%&4V8X-6[VSBU"SEM9US'(,&K'>CM6#G)VUV.A0BKJVY@0^'KI?)AFU69[2
M$@K&!@G'0$U;T[18]/>](D9Q=.6(Z8]JU.U'I5.K-JS9,:,(NZ1S;^%9GA-F
MVI2-8[]WE,H)ZYQFIKCPT1=_:=.O'LY&0(X49#`5O=Z.]5[>IW)^KT^QSO\`
MPB5N+.&%9WWI.)GD(Y<U=U#0X]0U&VNY)&`A1DVC^(&M7M1VI>VG>]_Z92H4
MTK6_I',IX2<6#Z>VHRFS.2D84#!]S4R>%T67S&N6)^R_9^GZUT'I1WINO4?4
ME8:DNARA\&,'MFCU&16MUPGR@@'UJW)X:EN8-MWJ,LLJ,'ADP`8S70=Z.U#Q
M%1]06&I+9&+#H4TDS2:C?R77R%`F-JX/M5`^#F>S>R;4IC:=8X\?=KJ>U'I0
MJ]1;,'AZ;W1GS:6LVAG3#(0IB\O?_6LZX\)P7!TTM,V;(`=/O@5T/>CO4QJS
MCLRI482W1B-X:MY;G4))G+)>``K_`'<>E1P^'KH&&.?5)I+:$@I&!@G'0$UO
M]J.U/VT^XO84[WL<\_A8K=SO;7\L%M<',L*CJ?:FV_A**"*RC%PQ%K,91Q][
M/:NC]*.]/V]2VXOJ]*]['.R^%Y$GN#8ZC+;0W!S)&!GGOBI%\+V\<UH\<KA;
M>-DP>=V>];W>CM2]O4[C^KT^QBQ>'DB\.RZ1Y[%9,_O,<\G-1R>&]IMIK2[>
MWNH(Q'Y@&=X]Q6]VH]*/;3[C]A3[&"OAE9,O=WUQ-,QR6#;1^5%;QHH]M4[B
&]A3['__9
`
end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
